Novoheart Limited is incorporated in Hong Kong on 2 January 2014, with the vision of revolutionizing drug discovery and development of heart therapeutics with proprietary bioengineered human heart constructs, and further developing them into transplantable grafts for cell-based regenerative therapies with superior safety and efficacy.